Microglial Annexin A3 promoted the development of melanoma via activation of hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Xu B;Xu B; Zhang X; Zhang X; Gao Y; Gao Y; Song J; Song J; Shi B; Shi B
  • Source:
    Journal of clinical laboratory analysis [J Clin Lab Anal] 2021 Feb; Vol. 35 (2), pp. e23622. Date of Electronic Publication: 2020 Oct 29.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: United States NLM ID: 8801384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2825 (Electronic) Linking ISSN: 08878013 NLM ISO Abbreviation: J Clin Lab Anal Subsets: MEDLINE
    • Publication Information:
      Publication: Hoboken, N.J. : Wiley
      Original Publication: New York : Alan R. Liss, Inc., c1987-
    • Subject Terms:
      Annexin A3/*metabolism ; Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism ; Melanoma/*metabolism ; Melanoma/*pathology ; Skin Neoplasms/*metabolism ; Skin Neoplasms/*pathology ; Vascular Endothelial Growth Factor A/*metabolism; Annexin A3/blood ; Annexin A3/genetics ; Case-Control Studies ; Cell Line, Tumor ; Cell Movement ; Humans ; Melanoma/mortality ; Skin Neoplasms/mortality ; Melanoma, Cutaneous Malignant
    • Abstract:
      Background: Melanoma, a relatively common malignancy, has become one of the tumors with the fastest rising incidence in recent years. The purpose of this study was to investigate the effect of Microglial Annexin A3 (ANXA3) on melanoma.
      Methods: Serum samples were obtained from 20 patients with melanoma or 20 healthy controls. Kaplan-Meier survival analysis was performed. Transcriptome were used to analyze the correlation between ANXA3 expression and overall survival in patients with melanoma. Human melanoma cell lines WM-115 cells were transfected with ANXA3, si-ANXA3, ANXA3 + si-hypoxia inducible factor-1α (HIF-1α), si-ANXA3 + HIF-1α, and negative plasmids. Cell proliferation assay, cell invasion assay, and wound healing assay were performed on WM-115 cells. Lactate dehydrogenase (LDH) and caspase-3/9 activities were detected by commercial kits. Western blot and RT-PCR were used to detect the protein and mRNA expression of relation factors.
      Results: ANXA3 expression was up-regulated in patients with melanoma in comparison with healthy controls. Over-expression of ANXA3 promoted cell growth and migration, and reduced cytotoxicity of WM-115 cells. Overall survival (OS) and disease-free survival (DFS) of patients with high ANXA3 expression were both lower than those of patients with low ANXA3 expression. Down-regulation of ANXA3 reduced cell growth and migration, and promoted cytotoxicity of WM-115 cells. ANXA3 induced vascular endothelial growth factor (VEGF) signaling pathway by activation of HIF-1α.
      Conclusion: In conclusion, our results indicated that ANXA3 promoted cell growth and migration of melanoma via activation of HIF-1α/VEGF signaling pathway.
      (© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, LLC.)
    • References:
      Science. 2016 Oct 21;354(6310):358-362. (PMID: 27846573)
      Am J Physiol Gastrointest Liver Physiol. 2016 Mar 1;310(5):G310-22. (PMID: 26702135)
      Oncol Rep. 2013 Nov;30(5):2467-75. (PMID: 24002546)
      Biomed Pharmacother. 2018 Jan;97:1397-1408. (PMID: 29156529)
      Oncol Rep. 2017 Feb;37(2):657-670. (PMID: 27959421)
      Diabetologia. 2016 Mar;59(3):644-54. (PMID: 26687158)
      Cent Eur J Immunol. 2017;42(1):30-38. (PMID: 28680329)
      Glia. 2017 Mar;65(3):523-530. (PMID: 28063215)
      Eur J Pharmacol. 2017 Jul 15;807:159-167. (PMID: 28414055)
      Free Radic Res. 2017 May;51(5):517-528. (PMID: 28482716)
      Food Chem Toxicol. 2014 Jan;63:166-73. (PMID: 23978414)
      Oncotarget. 2016 Nov 22;7(47):76508-76522. (PMID: 27793014)
      J Clin Lab Anal. 2021 Feb;35(2):e23622. (PMID: 33118214)
      Aliment Pharmacol Ther. 2017 Apr;45(8):1073-1083. (PMID: 28225186)
      Inflamm Bowel Dis. 2016 Sep;22(9):2098-105. (PMID: 27482975)
      World J Gastroenterol. 2013 Jul 21;19(27):4289-99. (PMID: 23885139)
      Oncotarget. 2015 May 20;6(14):12188-95. (PMID: 25893380)
      Pharmacol Res. 2015 Oct;100:335. (PMID: 26318761)
      J Gastroenterol. 2018 Apr;53(4):465-474. (PMID: 29075900)
      FEBS Open Bio. 2017 Jun 05;7(7):1009-1016. (PMID: 28680813)
      Endocrine. 2014 Sep;47(1):70-80. (PMID: 24968737)
      Clin Exp Immunol. 2016 Aug;185(2):154-64. (PMID: 27148790)
      Molecules. 2017 Feb 10;22(2):. (PMID: 28208611)
      Mucosal Immunol. 2016 Sep;9(5):1218-33. (PMID: 26813339)
      Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3. (PMID: 27521509)
    • Grant Information:
      LY16H150006 Natural Science Foundation of Zhejiang Province; 2018247152 Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
    • Contributed Indexing:
      Keywords: ANXA3; HIF-1α; VEGF; cell growth; melanoma; migration
    • Accession Number:
      0 (ANXA3 protein, human)
      0 (HIF1A protein, human)
      0 (Hypoxia-Inducible Factor 1, alpha Subunit)
      0 (VEGFA protein, human)
      0 (Vascular Endothelial Growth Factor A)
      EC 3.1.4.43 (Annexin A3)
    • Publication Date:
      Date Created: 20201029 Date Completed: 20211029 Latest Revision: 20231213
    • Publication Date:
      20231215
    • Accession Number:
      PMC7891517
    • Accession Number:
      10.1002/jcla.23622
    • Accession Number:
      33118214